SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The co-primary endpoints of the cohort are objective response rate (ORR) and safety. It is supported by the US$5M Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award, an innovative program established to accelerate the development of new treatments for pancreatic cancer patients. It will be conducted in collaboration with AIO-Studien-gGmbH (AIO), a clinical trial group within the German Cancer Society, as part of GOBLET, a Phase 1/2 multiple indication study evaluating pelareorep-based combinations in gastrointestinal cancers.
Related Posts
PubMatic Announces Instacart Ads Integration To Leverage Retail Media Data Across CTV
PubMatic (NASDAQ:PUBM), an independent technology company delivering digital advertising's supply chain of the future, today announced a new partnership with Instacart (NASDAQ:CART) to leverage its first-party,
Mizuho Maintains Buy on Zurn Elkay Water, Lowers Price Target to $26
Mizuho analyst Brett Linzey maintains Zurn Elkay Water (NYSE:ZWS) with a Buy and lowers the price target from $31 to $26.
Why Nano-X Imaging Stock Is Surging Monday
Shares of medical imaging technology company Nano-X Imaging Ltd (NASDAQ: NNOX) are trading higher Monday after the company said it received 510(k) clearance from the FDA to market the Nanox.ARC as a